Nanogen sells licenses to Quest Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Molecular diagnostics firm Nanogen will license its proprietary MGB Probe in vitro diagnostic technology to Quest Diagnostics for an undisclosed upfront fee and royalties on tests sold using the licensed technology, Nanogen said March 4. On March 6, the firm reported unaudited 2008 full-year revenues of $46.9 million, up 23%. Fourth-quarter revenues were $9.5 million, down 31% from the previous quarter